top of page

The chief medical officer of Astellas previews ASCO and talks about new modalities and targets the company has been working on

Tadaaki Taniguchi covers some of the work Astellas is doing with modalities like antibody-drug conjugates, T-cell engagers, and protein degradation, and targets such as Claudin 18.2.


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight


Breakthrough Properties is a life science real estate company that is exclusively focused on delivering cutting-edge environments for the life science industry. With a portfolio of roughly 5 million square feet across the US, UK and continental Europe, Breakthrough has emerged as a leading partner for high-growth biotechs and pharmas around the world. 

bottom of page